High-Throughput Screening (HTS) and Hit Validation to Identify Small Molecule Inhibitors with Activity against NS3/4A proteases from Multiple Hepatitis C Virus Genotypes
Open Access
- 9 October 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (10), e75144
- https://doi.org/10.1371/journal.pone.0075144
Abstract
Development of drug-resistant mutations has been a major problem with all currently developed Hepatitis C Virus (HCV) NS3/4A inhibitors, including the two FDA approved drugs, significantly reducing the efficacy of these inhibitors. The high incidence of drug-resistance mutations and the limited utility of these inhibitors against only genotype 1 highlight the need for novel, broad-spectrum HCV therapies. Here we used high-throughput screening (HTS) to identify low molecular weight inhibitors against NS3/4A from multiple genotypes. A total of 40,967 compounds from four structurally diverse molecular libraries were screened by HTS using fluorescence-based enzymatic assays, followed by an orthogonal binding analysis using surface plasmon resonance (SPR) to eliminate false positives. A novel small molecule compound was identified with an IC50 value of 2.2 µM against the NS3/4A from genotype 1b. Mode of inhibition analysis subsequently confirmed this compound to be a competitive inhibitor with respect to the substrate, indicating direct binding to the protease active site, rather than to the allosteric binding pocket that was discovered to be the binding site of a few recently discovered small molecule inhibitors. This newly discovered inhibitor also showed promising inhibitory activity against the NS3/4As from three other HCV genotypes, as well as five common drug-resistant mutants of genotype 1b NS3/4A. The inhibitor was selective for NS3 from multiple HCV genotypes over two human serine proteases, and a whole cell lysate assay confirmed inhibitory activity in the cellular environment. This compound provides a lead for further development of potentially broader spectrum inhibitors.This publication has 37 references indexed in Scilit:
- Discovery of an allosteric mechanism for the regulation of HCV NS3 protein functionNature Chemical Biology, 2012
- Reducing agents affect inhibitory activities of compounds: Results from multiple drug targetsAnalytical Biochemistry, 2012
- A macrocyclic HCV NS3/4A protease inhibitor interacts with protease and helicase residues in the complex with its full-length targetProceedings of the National Academy of Sciences of the United States of America, 2011
- An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver DiseasesHepatology, 2011
- Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor bindingProceedings of the National Academy of Sciences of the United States of America, 2010
- Hepatitis C virus genotype frequency in Isfahan province of Iran: a descriptive cross-sectional studyVirology Journal, 2010
- Multimodel InferenceSociological Methods & Research, 2004
- UCSF Chimera?A visualization system for exploratory research and analysisJournal of Computational Chemistry, 2004
- Improved protein–ligand docking using GOLDProteins-Structure Function and Bioinformatics, 2003
- Structural characterization of the interactions of optimized product inhibitors with the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein by NMR and modelling studiesJournal of Molecular Biology, 1999